Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54

Endocrinology

Volumn 148, Issue 3, 2007, Pages 1340-1349

  Yang, Zhiming ^a,b   Chang, Yu Jia ^a,c   Miyamoto, Hiroshi ^a   Yeh, Shuyuan ^a   Yao, Jorge L ^a   Di Sant'Agnese, P Anthony ^a   Tsai, Meng Yin ^d   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR COREGULATOR ARA54; HORMONE RECEPTOR AFFECTING AGENT; NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN; RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN A1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; DIMERIZATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; WILD TYPE;

3T3 CELLS; ANIMALS; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 33847070096     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0716     Document Type: Article

References (49)

1. Jemal A, Siegal R, Ward E, Murray T, Xu J, Smigal C, Thun MJ 2006 Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424
3. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C 1992 Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147:798-803
4. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A 1996 Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129-135
5. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar M 1996 Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2:889-895
6. Sadi MV, Walsh PC, Barrack ER 1991 Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064
7. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193
8. Chang CS, Kokontis J, Liao ST 1988 Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326
9. Chang CS, Kokontis J, Liao ST 1988 Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 85:7211-7215
10. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
11. Hsiao PW, Chang C 1999 Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 274:22373-22379
12. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C 1999 Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274:8316-8321
13. Yeh S, Chang C 1996 Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521
14. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C 2001 Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J Biol Chem 276:40417-40423
15. Kang HY, Yeh S, Fujimoto N, Chang C 1999 Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576
16. Zhang Y, Yang Y, Yeh S, Chang C 2004 ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 24:1044-1057
17. Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, Chang C 2004 Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol 24:2202-2213
18. Lin HK, Hu YC, Lee DK, Chang C 2004 Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18:2409-2423
19. Aarnisalo P, Palvimo JJ, Janne OA 1998 CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95:2122-2127
20. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F 1998 CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273:31853-31859
21. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357
22. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/P300 in nuclear receptor signalling. Nature 383:99-103
23. Rowan BG, Weigel NL, O'Malley BW 2000 Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475-4483
24. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085-6097
25. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C 2002 A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 277:4609-4617
26. Fujimoto N, Mizokami A, Harada S, Matsumoto T 2001 Different expression of androgen receptor coactivators in human prostate. Urology 58:289-294
27. Mestayer C, Blanchere M, Jaubert F, Dufour B, Mowszowicz I 2003 Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 56:192-200
28. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H 2000 Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 45:124-131
29. Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y, Chang C 2002 Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 277: 15426-15431
30. Pinol-Roma S, Dreyfuss G 1992 Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355:730-732
31. Siomi MC, Eder PS, Kataoka N, Wan L, Liu Q, Dreyfuss G 1997 Transportin-mediated nuclear import of heterogeneous nuclear RNP proteins. J Cell Biol 138:1181-1192
32. Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A, Gambacorti-Passerini C, Calabretta B, Perrotti D 2002 hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 22:2255-2266
33. Hamilton BJ, Nagy E, Malter JS, Arrick BA, Rigby WF 1993 Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. J Biol Chem 268:8881-8887
34. Izaurralde E, Jarmolowski A, Beisel C, Mattaj IW, Dreyfuss G, Fischer U 1997 A role for the M9 transport signal of hnRNP A1 in mRNA nuclear export. J Cell Biol 137:27-35
35. Ford LP, Wright WE, Shay JW 2002 A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene 21:580-583
36. Svitkin YV, Ovchinnikov LP, Dreyfuss G, Sonenberg N 1996 General RNA binding proteins render translation cap dependent. EMBO J 15:7147-7155
37. Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang X, Chang C 2003 The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 278:23691-23698
38. Thin TH, Kim E, Yeh S, Sampson ER, Chen YT, Collins LL, Basavappa R, Chang C 2002 Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17β-estradiol-induced androgen receptor transactivation. J Biol Chem 277:36499-36508
39. Yeh S, Miyamoto H, Shima H, Chang C 1998 From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95:5527-5532
40. Ting HJ, Yeh S, Nishimura K, Chang C 2002 Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA 99:661-666
41. Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C 2003 Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 63:4888-4894
42. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C 2003 Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 278:19619-19626
43. Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C 1999 Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11:195-202
44. Xie S, Lin HK, Ni J, Yang L, Wang L, di Sant'Agnese PA, Chang C 2004 Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate 60:61-67
45. Hellerstedt BA, Pienta KJ 2002 The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179
46. Kelly WK, Scher HI 1993 Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607-609
47. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H 1993 Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550
48. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
49. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515